<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Ovarian Cancer

Community    Breast Cancer    Ovarian Cancer

What Women of Eastern European Jewish Ancestry Should Know About Their Cancer Risk

All women need to pay attention to their risk factors for breast cancer and ovarian cancer, but women of Eastern European (Ashkenazi) Jewish ancestry should be especially vigilant, says University of Colorado Cancer Center member Marie Wood, MD, as their risk for having a genetic variant in the BRCA1 or BRCA2 genes is increased, predisposing them to developing hereditary breast and ovarian cancer.


Author Greg Glasgow | Publish Date May 06, 2024
Full Story

Colorectal Cancer    Ovarian Cancer

HIPEC Procedure Pumps Chemotherapy Into the Abdomen to Kill Cancer Cells

Cancers located in the abdomen — including colorectal cancer, appendix cancer, gastric cancer, and gynecologic cancers such as certain types of ovarian cancer — can be difficult to treat with traditional chemotherapy when the tumors spread beyond the organ in which they originated.


Author Greg Glasgow | Publish Date February 08, 2024
Full Story

Research    Gynecologic Cancer    Magazine    Ovarian Cancer

Innovations in Ovarian Cancer Research

Ovarian cancer is a growing area of research at the University of Colorado Cancer Center. A newly formed Ovarian Cancer Innovations Group, envisioned by Saketh Guntupalli, MD, and led by Kian Behbakht, MD, MBA, is taking a multipronged approach to studying the disease.


Author Greg Glasgow | Publish Date November 27, 2023
Full Story

Research    Ovarian Cancer

CU Cancer Center Researchers Land Major Grant to Investigate Ovarian Cancer Disparities

A pair of University of Colorado Cancer Center researchers have received a major grant to fund the next five years of their long-running research into a genetic risk factor for ovarian cancer that varies greatly across different ethnic communities – research that they hope will lead to better-targeted therapies.


Author Mark Harden | Publish Date November 20, 2023
Full Story

Patient Care    Magazine    Ovarian Cancer

CU Cancer Center Care Team Provides a Foundation for Healing for BRCA1-positive Patient

Amy Bibbey has two distinct lives. There’s the life she led before ovarian cancer, and there’s everything after diagnosis.


Author Carie Behounek | Publish Date September 21, 2023
Full Story

Research    Ovarian Cancer    Multiple Myeloma

Guidelines for Preventing Blood Clots in People With Cancer 

Many of the side effects of cancer treatment are well-known, including nausea, fatigue, and weight loss. 


Author Greg Glasgow | Publish Date July 28, 2023
Full Story

Patient Care    Ovarian Cancer    Immunotherapy    Genetics

Innovative Immunotherapy Treatment Helps Ovarian Cancer Patient See Amazing Results

People often tell Winona Williams that she’s brave, and she is. Ovarian cancer could easily become a dark cloud over her, shadowing every minute of every day.


Author Rachel Sauer | Publish Date September 20, 2022
Full Story

Press Releases    Pediatric Cancer    Blood Cancer    Brain and Spinal Cancer    Ovarian Cancer

CU Cancer Center Researchers Awarded Grants From V Foundation

Three researchers from the University of Colorado Cancer Center have received grants from the V Foundation, a cancer research nonprofit founded in 1993 by college basketball coach Jimmy Valvano, who died of cancer.


Author Greg Glasgow | Publish Date October 20, 2021
Full Story

Research    Cancer    Ovarian Cancer

Innovative Ovarian Cancer Research Newly Supported by R37 MERIT Award

One of the most impactful advancements during the past decade in treating ovarian cancer is the use of PARP inhibitors (short for poly adenosine diphosphate-ribose polymerase). PARP inhibitors are a type of cancer drug that blocks the PARP enzyme from helping to repair DNA damage in cancer cells.


Author Rachel Sauer | Publish Date September 13, 2021
Full Story

Research    Gynecologic Cancer    Ovarian Cancer

CU Researchers Come Together to Better Understand Ovarian Cancer Tumors and Treatment Outcomes

After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response.


Author Cancer Center | Publish Date September 15, 2020
Full Story

Philanthropy    Gynecologic Cancer    Cancer    Ovarian Cancer

Building Towards Early Detection of Ovarian Cancer

In July 2019, Emily McClintock Addlesperger was on vacation in Maine with her husband, Jason, when she felt sick and was airlifted to Portland with internal bleeding. A tumor on her ovary had burst. It was Monday. On Saturday, she passed away. Emily was 44 years old.


Author Cancer Center | Publish Date July 16, 2020
Full Story

Research    Women's Health    Ovarian Cancer

Experimental medication to prevent heart disease may treat chemo-resistant ovarian cancer

Most ovarian cancer starts in fallopian tubes. Then it sloughs from its site of origin and floats around in fluid until finding new sites of attachment. It’s not easy for cancer cells to survive away from their moorings. Observations by ovarian cancer doctors at University of Colorado Cancer Center and elsewhere hint at how they might do it: These doctors have seen that ovarian cancer cells often collect in tissues with high fat content. Could these cells be somehow using fat to survive the journey from their point of origin to their sites of growth? 


Author Cancer Center | Publish Date March 26, 2020
Full Story

Clinical Trials    Ovarian Cancer

ASCO: Phase 1 clinical trials benefit patients with aggressive ovarian cancer

Patients with recurrent, heavily pretreated ovarian cancer generally have few therapeutic options.  Phase 1 clinical trials are considered by some providers as a “last hope.” Historically, there has been concern that there is little clinical benefit to these trials and high concern of toxicity, as these are typically first in human studies. However, these worries may be unnecessary.  A University of Colorado Cancer Center study presented at the American Society of Clinical Oncology (ASCO) conference in Chicago indicates that there are therapeutic benefits for ovarian cancer patients that enroll in Phase 1 clinical trials.  


Author Cancer Center | Publish Date May 30, 2019
Full Story

CU Cancer Center In the News

OncLive

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

news outletOncLive
Publish DateJuly 08, 2024

CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.

Full Story
News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story
Cancer Health

2024 Cancer Health 25: People Who Power Clinical Trials

news outletCancer Health
Publish DateJune 11, 2024

This year's Cancer Health 25 highlights the transformative power and promise of clinical trials. University of Colorado Cancer Center member Jessica McDermott, MD, MSCS, is leading clinical trials at both the CU Cancer Center and the Rocky Mountain Regional Veterans Affairs Medical Center. Additionally, she serves as the CU Cancer Center's deputy associate director for diversity and inclusion in clinical research.

Full Story